GAMMA Investing’s XTL Biopharmaceuticals XTLB Stock Holding History

GAMMA Investing’s Portfolio XTLB Stock Details XTLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.9K	Buy	3,436 +2,223	+183%	+$6K	﹤0.01%	3470
2026 Q2	$3.31K	Sell	1,213 -2,175	-64%	-$5.6K	﹤0.01%	3620
2026 Q1	$8.16K	Buy	3,388 +166	+5%	+$526	﹤0.01%	3177
2025 Q4	$7.47K	Buy	+3,222	New	+$13K	﹤0.01%	3109

Other funds holding XTLB

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

GAMMA Investing's XTLB Position: Q3 2026 in Review

GAMMA Investing increased its XTL Biopharmaceuticals (XTLB) stake by 183% in Q3 2026, buying an estimated $6K and bringing the position to 3,436 shares worth $7.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3470.

GAMMA Investing first reported a position in XTLB in Q4 2025 and has held it in 4 quarters since. The position peaked at $8.16K in Q1 2026. 3 funds tracked by Wall St. Rank hold XTLB as of Q3 2026.

GAMMA Investing held 3,436 shares of XTL Biopharmaceuticals worth $7.9K as of Q3 2026.
GAMMA Investing bought 2,223 XTL Biopharmaceuticals shares in Q3 2026, an estimated $6K.
XTL Biopharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3470 holding.
GAMMA Investing first reported a position in XTL Biopharmaceuticals in Q4 2025 and has held it in 4 quarters since.
GAMMA Investing's XTL Biopharmaceuticals position peaked at $8.16K in Q1 2026.
3 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.